↓ Skip to main content

G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts

Overview of attention for article published in PLOS ONE, June 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (85th percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

news
1 news outlet
twitter
2 X users
facebook
1 Facebook page

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
25 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts
Published in
PLOS ONE, June 2016
DOI 10.1371/journal.pone.0157245
Pubmed ID
Authors

Alessia Zoso, Paolo Serafini, Giacomo Lanzoni, Eduardo Peixoto, Shari Messinger, Alejandro Mantero, Nathalia D. Padilla-Téllez, David A. Baidal, Rodolfo Alejandro, Camillo Ricordi, Luca Inverardi

Abstract

Allogeneic human islet transplantation is an effective therapy for the treatment of patients with Type 1 Diabetes (T1D). The low number of islet transplants performed worldwide and the different transplantation protocols used limit the identification of the most effective therapeutic options to improve the efficacy of this approach. We present a retrospective analysis on the data collected from 44 patients with T1D who underwent islet transplantation at our institute between 2000 and 2007. Several variables were included: recipient demographics and immunological characteristics, donor and transplant characteristics, induction protocols, and additional medical treatment received. Immunosuppression was induced with anti-CD25 (Daclizumab), alone or in association with anti-tumor necrosis factor alpha (TNF-α) treatments (Etanercept or Infliximab), or with anti-CD52 (Alemtuzumab) in association with anti-TNF-α treatments (Etanercept or Infliximab). Subsets of patients were treated with Filgrastim for moderate/severe neutropenia and/or Exenatide for post prandial hyperglycemia. The analysis performed indicates a negative association between graft survival (c-peptide level ≥ 0.3 ng/ml) and islet infusion volume, with the caveat that, the progressive reduction of infusion volumes over the years has been paralleled by improved immunosuppressive protocols. A positive association is instead suggested between graft survival and administration of Exenatide and Filgrastim, alone or in combination. This retrospective analysis may be of assistance to further improve long-term outcomes of protocols for transplant of islets and other organs.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 25 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 3 12%
Student > Bachelor 3 12%
Other 2 8%
Student > Master 2 8%
Student > Doctoral Student 1 4%
Other 4 16%
Unknown 10 40%
Readers by discipline Count As %
Medicine and Dentistry 8 32%
Biochemistry, Genetics and Molecular Biology 1 4%
Agricultural and Biological Sciences 1 4%
Nursing and Health Professions 1 4%
Immunology and Microbiology 1 4%
Other 1 4%
Unknown 12 48%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 June 2016.
All research outputs
#2,783,722
of 22,877,793 outputs
Outputs from PLOS ONE
#35,858
of 195,158 outputs
Outputs of similar age
#51,213
of 345,199 outputs
Outputs of similar age from PLOS ONE
#820
of 4,669 outputs
Altmetric has tracked 22,877,793 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 195,158 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.1. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 345,199 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 4,669 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.